OBJECTIVE: The cytochromes P450 epoxygenases CYP2J2 and CYP2C8 synthesize epoxyeicosatrienoic acids, which regulate endothelial function. We sought to determine if genetic variation in CYP2J2 and CYP2C8 was associated with coronary heart disease risk. METHODS: We genotyped 2065 Atherosclerosis Risk in Communities study participants (1085 incident coronary heart disease cases, 980 noncases) for polymorphisms in CYP2J2 and CYP2C8. Using a case-cohort design, associations between genotype and incident coronary heart disease risk were evaluated using proportional hazards regression. The influence of cigarette smoking on these associations was also evaluated. False discovery rate q-values were estimated to minimize the impact of the multiple statistical comparisons completed. All analyses were race stratified. RESULTS: The CYP2J2 G-50T polymorphism variant -50T allele was associated with significantly lower risk of incident coronary heart disease in African-Americans (adjusted hazard rate ratio 0.58, 95% confidence interval 0.35-0.96, P=0.036, q=0.051); however, no significant association was observed in Caucasians. Overall, the I264M, I269F, and K399R polymorphisms in CYP2C8 were not significantly associated with risk of incident coronary heart disease. In Caucasians, the relationship between the I264M and K399R polymorphisms and incident coronary heart disease risk was significantly modified by cigarette smoking status (P for interaction=0.008, q=0.064), with the highest risk observed in smokers carrying at least one variant allele. CONCLUSIONS: The G-50T polymorphism in CYP2J2 may be an important risk factor for the development of coronary heart disease events in African-Americans, whereas cigarette smoking may modify the relationship between the I264M and K399R polymorphisms in CYP2C8 and coronary heart disease risk in Caucasians. Confirmation of these findings in an independent population is warranted.
OBJECTIVE: The cytochromes P450 epoxygenases CYP2J2 and CYP2C8 synthesize epoxyeicosatrienoic acids, which regulate endothelial function. We sought to determine if genetic variation in CYP2J2 and CYP2C8 was associated with coronary heart disease risk. METHODS: We genotyped 2065 Atherosclerosis Risk in Communities study participants (1085 incident coronary heart disease cases, 980 noncases) for polymorphisms in CYP2J2 and CYP2C8. Using a case-cohort design, associations between genotype and incident coronary heart disease risk were evaluated using proportional hazards regression. The influence of cigarette smoking on these associations was also evaluated. False discovery rate q-values were estimated to minimize the impact of the multiple statistical comparisons completed. All analyses were race stratified. RESULTS: The CYP2J2G-50T polymorphism variant -50T allele was associated with significantly lower risk of incident coronary heart disease in African-Americans (adjusted hazard rate ratio 0.58, 95% confidence interval 0.35-0.96, P=0.036, q=0.051); however, no significant association was observed in Caucasians. Overall, the I264M, I269F, and K399R polymorphisms in CYP2C8 were not significantly associated with risk of incident coronary heart disease. In Caucasians, the relationship between the I264M and K399R polymorphisms and incident coronary heart disease risk was significantly modified by cigarette smoking status (P for interaction=0.008, q=0.064), with the highest risk observed in smokers carrying at least one variant allele. CONCLUSIONS: The G-50T polymorphism in CYP2J2 may be an important risk factor for the development of coronary heart disease events in African-Americans, whereas cigarette smoking may modify the relationship between the I264M and K399R polymorphisms in CYP2C8 and coronary heart disease risk in Caucasians. Confirmation of these findings in an independent population is warranted.
Authors: Namrata Bahadur; Julian B S Leathart; Elaine Mutch; Dorothy Steimel-Crespi; Stuart A Dunn; Ron Gilissen; Jos Van Houdt; Jan Hendrickx; Geert Mannens; Hilde Bohets; Faith M Williams; Martin Armstrong; Charles L Crespi; Ann K Daly Journal: Biochem Pharmacol Date: 2002-12-01 Impact factor: 5.858
Authors: Z Yu; F Xu; L M Huse; C Morisseau; A J Draper; J W Newman; C Parker; L Graham; M M Engler; B D Hammock; D C Zeldin; D L Kroetz Journal: Circ Res Date: 2000-11-24 Impact factor: 17.367
Authors: Lorraine M King; Jixiang Ma; Supawon Srettabunjong; Joan Graves; J Alyce Bradbury; Leping Li; Martin Spiecker; James K Liao; Harvey Mohrenweiser; Darryl C Zeldin Journal: Mol Pharmacol Date: 2002-04 Impact factor: 4.436
Authors: Craig R Lee; Kari E North; Molly S Bray; Christy L Avery; Mary Jane Mosher; David J Couper; Josef Coresh; Aaron R Folsom; Eric Boerwinkle; Gerardo Heiss; Darryl C Zeldin Journal: Pharmacogenet Genomics Date: 2006-12 Impact factor: 2.089
Authors: Julian P J Halcox; William H Schenke; Gloria Zalos; Rita Mincemoyer; Abhiram Prasad; Myron A Waclawiw; Khaled R A Nour; Arshed A Quyyumi Journal: Circulation Date: 2002-08-06 Impact factor: 29.690
Authors: Ahmad Hanif; Matthew L Edin; Darryl C Zeldin; Christophe Morisseau; Mohammed A Nayeem Journal: Am J Physiol Regul Integr Comp Physiol Date: 2016-08-03 Impact factor: 3.619
Authors: Mohammed A Nayeem; Isha Pradhan; S Jamal Mustafa; Christophe Morisseau; John R Falck; Darryl C Zeldin Journal: Am J Physiol Regul Integr Comp Physiol Date: 2012-11-14 Impact factor: 3.619
Authors: Ara Askari; Scott J Thomson; Matthew L Edin; Darryl C Zeldin; David Bishop-Bailey Journal: Prostaglandins Other Lipid Mediat Date: 2013-03-06 Impact factor: 3.072
Authors: Jessica A Wray; Mary C Sugden; Darryl C Zeldin; Gemma K Greenwood; Salma Samsuddin; Laura Miller-Degraff; J Alyce Bradbury; Mark J Holness; Timothy D Warner; David Bishop-Bailey Journal: PLoS One Date: 2009-10-12 Impact factor: 3.240